慢性疼痛治疗​​的全球市场：市场规模和占有率分析 - 趋势、驱动因素、竞争格局、未来预测（2024-2030）

市场概况

全球慢性疼痛治疗​​市场预计2023年营收将达976亿美元，2030年将达1596亿美元，2024年至2030年复合年增长率为7.4%。 该产业发展的关键原因包括政府对这些解决方案的支持力度增加、老年人口不断增加以及慢性病发病率上升。

关键见解

由于严重头痛、背痛和脸部疼痛等慢性疼痛疾病的增加，药品类别预计将以约 7.7% 的复合年增长率增长，并引领行业占有率。

2023年，由于纤维肌痛、骨关节炎和类风湿关节炎等肌肉骨骼疾病的高发，肌肉骨骼类别的占有率为40%。

从2019年到2021年，美国有5,320万成年人将患有上述疾病：不同类型的关节炎（包括类风湿性关节炎）、痛风、红斑性狼疮或纤维肌痛症。

由于关节炎盛行率不断上升以及腰痛成为全球残疾的主要原因等因素，预计到预测期结束时，肌肉骨骼领域的复合年增长率将达到 7.3%。

根据迹象，癌症疼痛类别预计在预测期内将以 8.0% 的复合年增长率增长。

依地区划分，在医疗基础设施进步、可支配收入增加、老年人口增长和慢性疼痛患病率的推动下，亚太地区在预测期内将以 7.8% 的复合年增长率增长最快。

到 2023 年，北美地区将占该行业占有率的 55%，该地区因其发达的医疗基础设施、高昂的医疗成本以及广泛的先进疼痛治疗解决方案而受到青睐。

本报告分析了全球慢性疼痛治疗​​市场，包括市场的基本结构和最新情况、主要促进和抑制因素以及全球、依地区和主要国家的市场规模前景（以货币形式计算） ，2017-2030） ，依细分市场划分的详细趋势、当前市场竞争状况以及主要公司概况。

目录

第一章研究范围

第二章研究方法

第 3 章执行摘要

第 4 章市场指标

第五章产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/课题
  • 促进/抑制因子影响分析
• 新型冠状病毒感染 (COVID-19) 的影响
• 波特五力分析

第六章世界市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依指标分类（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：依分销管道划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依地区划分（2017-2030 年）

第七章北美市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依指标分类（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：依分销管道划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第十一章中东及非洲市场

第12章美国市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依指标分类（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：依分销管道划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）

第十三章加拿大市场

第14章德国市场

第十五章法国市场

第十六章英国市场

第十七章义大利市场

第十八章西班牙市场

第十九章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

• 市场参与者及其提供的产品/服务的列表
• 主要公司的竞争基准
• 各大公司的产品基准
• 近期策略发展状况

第30章公司简介

• Eli Lilly and Company
• GlaxoSmithKline plc
• Pfizer Inc.
• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• Novartis AG
• Johnson & Johnson Services Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Becton, Dickinson and Company
• Sanofi S.A.
• Teva Pharmaceutical Industries Limited
• AbbVie Inc.
• Paradigm Biopharmaceuticals Limited

第31章附录

Market Overview

The chronic pain treatment market achieved a revenue of USD 97.6 billion in 2023 and is projected to experience a compound annual growth rate (CAGR) of 7.4% from 2024 to 2030, reaching USD 159.6 billion by 2030. The major reasons accountable for the development of the industry include the growing government backing for these solutions, increasing elderly populace, and rising occurrence of chronic health conditions.

The industry players have been constantly spending in emerging innovative items for chronic pain treatment. Wearable tech for the treatment of long-lasting pain is one of the major improvements in the chronic pain treatment industry.

The World Health Organization projects a substantial surge in the worldwide populace aged 60 and more from 12% to 22% between 2015 and 2050. This demographic move has augmented the occurrence of chronic pain, mainly among elder patients in nursing homes, posing a challenge for care facilities.

To confront this problem, a combination of pharmacological, non-pharmacological (physical and occupational therapies), and occupational therapies is employed, positively impacting the chronic pain treatment market.

Chronic illnesses such as sickle-cell anemia, osteoarthritis, fibromyalgia, cancer, and autoimmune illnesses such as rheumatoid arthritis are dominant worldwide, requiring therapeutic interventions for better pain management. The extensive use of treatments such as physiotherapy, medication, and psychological therapy reflects the rising load of chronic diseases and their impact on healthcare systems globally.

Key Insights

The drugs category is projected to advance at a CAGR of around 7.7% and lead the industry share because of increasing chronic pain cases such as severe headaches, lower back pain, and facial pain.

Reasons contributing to this development include the growing worldwide elderly populace, sedentary lifestyles, and an increase in surgical procedures.

The need for painkillers is projected to intensify in response to these trends over the forecast period.

In 2023, the musculoskeletal category had a 40% industry share because of the high occurrence of musculoskeletal illnesses such as fibromyalgia, osteoarthritis, and rheumatoid arthritis.

In 2019-2021, as many as 53.2 million U.S. adults had these conditions: different kinds of arthritis (including rheumatoid arthritis), gout, lupus or fibromyalgia, according to NHIS (National Health Interview Survey).

Musculoskeletal segment is predicted to have a CAGR of 7.3% until the end of the forecast period due to some factors e.g. increase arthritis prevalence and back pain which is responsible for disability all over the world being at the top.

During the projection period, the cancer pain category is projected to advance at a CAGR of 8.0% based on indication.

The National Cancer Institute classifies cancer as a principal worldwide reason of death, with forecasts indicating increasing new cases and demises by 2040.

Growing cancer survivor numbers contribute to industry development because of the long-lasting and commonly severe pain related with the disease.

The APAC region is set to be the fastest-growing industry with a CAGR of 7.8% during the projection period, propelled by advancing healthcare infrastructure, increasing disposable income, rising elderly populace, and growing chronic pain prevalence.

Asia's elderly populace is projected to double from 395 million in 2019 to 587 million by 2030, paying to advanced demand for pain treatment medications and devices.

In 2023, the North American region, holding a 55% industry share, advantages from developed healthcare infrastructure, high healthcare spending, and extensive obtainability of advanced pain treatment solutions.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by indication
  • 1.4.3. Market size breakdown, by application
  • 1.4.4. Market size breakdown, by distribution channel
  • 1.4.5. Market size breakdown, by end user
  • 1.4.6. Market size breakdown, by region
  • 1.4.7. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Indication (2017-2030)
• 6.4. Market Revenue, by Application (2017-2030)
• 6.5. Market Revenue, by Distribution Channel (2017-2030)
• 6.6. Market Revenue, by End User (2017-2030)
• 6.7. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Indication (2017-2030)
• 7.4. Market Revenue, by Application (2017-2030)
• 7.5. Market Revenue, by Distribution Channel (2017-2030)
• 7.6. Market Revenue, by End User (2017-2030)
• 7.7. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Indication (2017-2030)
• 8.4. Market Revenue, by Application (2017-2030)
• 8.5. Market Revenue, by Distribution Channel (2017-2030)
• 8.6. Market Revenue, by End User (2017-2030)
• 8.7. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Indication (2017-2030)
• 9.4. Market Revenue, by Application (2017-2030)
• 9.5. Market Revenue, by Distribution Channel (2017-2030)
• 9.6. Market Revenue, by End User (2017-2030)
• 9.7. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Indication (2017-2030)
• 10.4. Market Revenue, by Application (2017-2030)
• 10.5. Market Revenue, by Distribution Channel (2017-2030)
• 10.6. Market Revenue, by End User (2017-2030)
• 10.7. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Indication (2017-2030)
• 11.4. Market Revenue, by Application (2017-2030)
• 11.5. Market Revenue, by Distribution Channel (2017-2030)
• 11.6. Market Revenue, by End User (2017-2030)
• 11.7. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Indication (2017-2030)
• 12.4. Market Revenue, by Application (2017-2030)
• 12.5. Market Revenue, by Distribution Channel (2017-2030)
• 12.6. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Indication (2017-2030)
• 13.4. Market Revenue, by Application (2017-2030)
• 13.5. Market Revenue, by Distribution Channel (2017-2030)
• 13.6. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Indication (2017-2030)
• 14.4. Market Revenue, by Application (2017-2030)
• 14.5. Market Revenue, by Distribution Channel (2017-2030)
• 14.6. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Indication (2017-2030)
• 15.4. Market Revenue, by Application (2017-2030)
• 15.5. Market Revenue, by Distribution Channel (2017-2030)
• 15.6. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Indication (2017-2030)
• 16.4. Market Revenue, by Application (2017-2030)
• 16.5. Market Revenue, by Distribution Channel (2017-2030)
• 16.6. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Indication (2017-2030)
• 17.4. Market Revenue, by Application (2017-2030)
• 17.5. Market Revenue, by Distribution Channel (2017-2030)
• 17.6. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Indication (2017-2030)
• 18.4. Market Revenue, by Application (2017-2030)
• 18.5. Market Revenue, by Distribution Channel (2017-2030)
• 18.6. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Indication (2017-2030)
• 19.4. Market Revenue, by Application (2017-2030)
• 19.5. Market Revenue, by Distribution Channel (2017-2030)
• 19.6. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Indication (2017-2030)
• 20.4. Market Revenue, by Application (2017-2030)
• 20.5. Market Revenue, by Distribution Channel (2017-2030)
• 20.6. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Indication (2017-2030)
• 21.4. Market Revenue, by Application (2017-2030)
• 21.5. Market Revenue, by Distribution Channel (2017-2030)
• 21.6. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Indication (2017-2030)
• 22.4. Market Revenue, by Application (2017-2030)
• 22.5. Market Revenue, by Distribution Channel (2017-2030)
• 22.6. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Indication (2017-2030)
• 23.4. Market Revenue, by Application (2017-2030)
• 23.5. Market Revenue, by Distribution Channel (2017-2030)
• 23.6. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Indication (2017-2030)
• 24.4. Market Revenue, by Application (2017-2030)
• 24.5. Market Revenue, by Distribution Channel (2017-2030)
• 24.6. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Indication (2017-2030)
• 25.4. Market Revenue, by Application (2017-2030)
• 25.5. Market Revenue, by Distribution Channel (2017-2030)
• 25.6. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Indication (2017-2030)
• 26.4. Market Revenue, by Application (2017-2030)
• 26.5. Market Revenue, by Distribution Channel (2017-2030)
• 26.6. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Indication (2017-2030)
• 27.4. Market Revenue, by Application (2017-2030)
• 27.5. Market Revenue, by Distribution Channel (2017-2030)
• 27.6. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Indication (2017-2030)
• 28.4. Market Revenue, by Application (2017-2030)
• 28.5. Market Revenue, by Distribution Channel (2017-2030)
• 28.6. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Eli Lilly and Company
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. GlaxoSmithKline plc
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Pfizer Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Medtronic plc
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Abbott Laboratories
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Boston Scientific Corporation
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Novartis AG
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Johnson & Johnson Services Inc.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. AstraZeneca PLC
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Bristol-Myers Squibb Company
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary
• 30.11. Becton, Dickinson and Company
  • 30.11.1. Business overview
  • 30.11.2. Product and service offerings
  • 30.11.3. Key financial summary
• 30.12. Sanofi S.A.
  • 30.12.1. Business overview
  • 30.12.2. Product and service offerings
  • 30.12.3. Key financial summary
• 30.13. Teva Pharmaceutical Industries Limited
  • 30.13.1. Business overview
  • 30.13.2. Product and service offerings
  • 30.13.3. Key financial summary
• 30.14. AbbVie Inc.
  • 30.14.1. Business overview
  • 30.14.2. Product and service offerings
  • 30.14.3. Key financial summary
• 30.15. Paradigm Biopharmaceuticals Limited
  • 30.15.1. Business overview
  • 30.15.2. Product and service offerings
  • 30.15.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports